Leukemias, lymphomas, and other hematologic cancers:
Indications for: POTELIGEO
In adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
Adult Dosage:
Premedicate with diphenhydramine and acetaminophen for the 1st infusion. Infuse IV over ≥60mins. 1mg/kg on Days 1, 8, 15, and 22 of the first 28-day cycle, then on Days 1 and 15 of each subsequent cycle until disease progression or unacceptable toxicity. Dose modifications for toxicity: see full labeling.
Children Dosage:
Not established.
POTELIGEO Warnings/Precautions:
Monitor for skin rash; permanently discontinue if SJS/TEN or life-threatening reaction (Grade 4) occurs. Monitor for infusion reactions; interrupt for any grade reaction and treat promptly; permanently discontinue for life-threatening reaction (Grade 4). Monitor for infection; treat promptly. History of autoimmune disease. Interrupt or permanently discontinue as appropriate if immune-mediated adverse reactions suspected. Complications of allogeneic HSCT after Poteligeo (including severe acute GVHD, steroid-refractory GVHD, transplant-related death); monitor closely. Verify pregnancy status prior to initiation. Advise females of reproductive potential to use effective contraception during and for 3 months after the last dose. Pregnancy: not recommended. Nursing mothers.
POTELIGEO Classification:
CCR4-directed monoclonal antibody.
Adverse Reactions:
Rash, infusion related reactions, fatigue, diarrhea, musculoskeletal pain, upper RTI, skin infection, pyrexia, nausea, edema, thrombocytopenia, headache, constipation, mucositis, anemia, cough, hypertension.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial—1
